Led · Series A · Dec 2022

Baishi Medical focuses on computer imaging artificial intelligence analysis for breast cancer, nasopharyngeal carcinoma and related areas. The company has accumulated labeled imaging databases and algorithms and works with domestic hospitals and medical imaging equipment firms. It announced completion of a strategic B round raising RMB 90 million (¥90M) from Zhuji Xienuo Xingshi Venture Investment Partnership, with Qingke Capital acting as exclusive financial adviser. Proceeds will be used to enhance and broaden the company’s product pipeline aimed at the global $100 billion intelligent tumor precision treatment market, and to expand domestic and international market coverage. Baishi plans to accelerate R&D, production and registration of integrated software-and-hardware intelligent tumor precision treatment solutions. The company will join Zhejiang’s Zhuji intelligent vision “10k mu 100 billion” new industry platform to advance its East China strategic layout and build R&D and production capabilities for precision surgical products. PVmed, launched in May 2017 and based in Guangzhou, China, develops AI-defined cancer treatment workflow products that automatically process and prepare 3D CT and MR data to help doctors plan and treat cancers. Its product portfolio includes iRT for Radiotherapy, iSA for Surgical Oncology, and iCS for Customized Oncology Software. The company’s solutions are deployed at over 200 hospitals in China and have processed more than 200,000 cancer patients. PVmed recently completed a sales and collaboration agreement with Tianjin Medical University Cancer Institute and Hospital. It intends to use the new funding to further develop its AI cancer treatment product portfolio and ecosystem and to accelerate adoption of its software and hardware by hospitals and medical-technology companies. The company raised US$14M in a Series A round to support these plans.

Participated · Series A · Mar 2022

CVAid Medical has developed an AI-driven platform that enables neurological examinations from smartphone video and voice recordings, processing image and audio data in the cloud with in-house algorithms for real-time analysis and comparison with stored medical records. The system provides clinicians with immediate diagnostic output on whether a patient has had a stroke and an assessment of severity, plus tools to support rapid treatment decisions. The technology is also designed for use by non-professionals (e.g., retirement-home staff or family members) to enable early detection, coordinate evacuation, and ready hospital teams before ambulance arrival. The company has conducted clinical trials at hospitals in Israel and Europe and has examined hundreds of patients. Led by CEO Oren Dror and founded in 2018, CVAid plans to expand operations and accelerate its business reach using the new funds.

Participated · Series B · Dec 2021

Babyscripts offers a mobile clinical solution for remote monitoring in pregnancy, combining a mobile app with internet-connected devices, digital education, and customized risk-specific experiences. The platform enables providers and payers to manage patients via risk-based care modules, remote monitoring, and automated care elements. Babyscripts reports managing more than 200K unique pregnancies across 30 states and says its tools can allow providers to manage up to 90% of pregnancies virtually. The solution is delivered via a joint deployment model that incorporates payers sponsoring platform use at participating sites to identify and triage member risk and improve care coordination. The company emphasizes targeting and reducing systemic racial and ethnic inequities in maternal and infant outcomes. Babyscripts intends to use the new funding to accelerate rollout of its Virtual Maternity Care solution across U.S. providers and to develop models specifically designed for payers; the company has raised $37M to date. Babyscripts offers a virtual maternity care platform that pairs medical-device kits (blood pressure, weight, captured blood sugars) with a mobile app to monitor and alert clinicians to maternal health issues. The platform can automate roughly 40%–50% of prenatal care and has been shown to accelerate diagnoses (for example, preeclampsia detected 13 days faster than standard care at a site). Babyscripts is used by 75 health systems across 32 states and monitors about 250,000 women annually; more than 70% of its patients are on Medicaid. The company expanded product lines from a single device to multiple targeted kits and recently launched a mental health product while developing a substance use disorder experience. Babyscripts has formed partnerships with public health departments, managed Medicaid plans and providers to enable local payment and broader deployment. The company grew enrollments 10x during the pandemic and has 45 employees, with plans to double headcount in the next 12–18 months to support product, payer growth, clinical expertise, implementation and customer success. Babyscripts builds a clinically validated virtual care platform that allows OBGYNs to deliver a new model of prenatal and postpartum care using internet-connected devices for remote monitoring. The platform offers risk-specific experiences and the company says it can allow providers to manage up to 90% of pregnancies virtually. Babyscripts has spent six years developing what it describes as the most-implemented mobile clinical solution for remote monitoring in pregnancy and was named to CB Insights' 2020 Digital Health 150. The company emphasizes partnering with physicians and health systems to guide product development and improve maternal outcomes. Its stated mission is to eliminate maternal mortality and expand access to care. Recent health-system partnerships are intended to align Babyscripts' roadmap with customer needs and support scaling of its virtual maternity care solutions. Babyscripts offers a clinically-validated virtual care obstetrics platform that uses internet-connected devices for remote monitoring to support prenatal and postpartum care. The core product delivers risk-specific experiences to allow OBGYNs to manage a large portion of pregnancies remotely. The system is designed to detect risk more quickly and automate elements of care, enabling providers to manage up to 90% of pregnancies virtually. Led by CEO and co-founder Anish Sebastian, the company has spent the last four years building this platform. Babyscripts recently acquired iBirth, expanding its offering to include a provider-delivered, co-branded pregnancy app and a more holistic pregnancy and postpartum program. Financially, Babyscripts raised $500K from Inova Health System, which will support deployment of the platform. Babyscripts develops a mobile app and remote-monitoring devices that track blood pressure and weight and deliver neonatal care information to expecting mothers. The company works with hospitals and healthcare providers to distribute its devices and software, creating a channel between patients and OBGYNs throughout pregnancy. Using remote monitoring, Babyscripts says it can tailor treatments to risk profiles and enable providers to manage up to 90% of pregnancies virtually. The platform is already being used to monitor 160,000 pregnancies across 20 states, and the company reports average patient engagement of six app or monitoring interactions per week. Leadership says the company will use funding to continue acquiring market share and build additional products for pregnancy patients, including postpartum and early-stage pediatric services through expanded offerings.

Participated · Series B · Sep 2021

Xealth is a Seattle-based company that develops digital health enablement solutions for health systems. Its platform allows providers to prescribe and monitor digital health content, apps, and services as easily as medications. The platform incorporates custom data and analytics so health systems can track, analyze, and evaluate digital health use through its integration platform. Led by CEO Mike McSherry, Xealth reports 12 million orders sent, 100,000 providers engaged, and three million patients reached to date. The company received an investment from Morningside Ventures and intends to use the funds to expand operations and its development efforts. The amount and instrument of the investment were not disclosed in the announcement. Xealth provides a platform that centralizes integration, prescribing, monitoring and governance for digital health tools within clinician workflows. The platform is tightly integrated with EHRs and has full integrations with the largest EHR vendors. It is available to more than 100,000 physicians and its deployments demonstrate a 50–80% reduction in integration and deployment costs while driving substantial patient engagement. Xealth is backed by health systems and strategic investors, including Cerner, Novartis, Philips, ResMed, McKesson Ventures, Threshold Ventures and LRV Health. The company plans to use the new funding to roughly double its team and to fund product innovation, including enhancements to its intelligence engine to better match tools to patients and scale deployments across the U.S. Spun out of Providence St. Joseph Health in 2017 and based in Seattle, Xealth has raised $52.6 million to date. Xealth provides a platform that enables health systems to organize, integrate, deploy and activate digital health tools and programs. Through the platform, clinicians can find and order digital health tools directly from the EHR workflow, send those digital orders to patients' smartphones or desktops, monitor patient engagement and analyze the effects of more engaged patients. The company raised an additional $3M in its Series A, bringing the round to $14M total, and intends to use the funds to advance development and deployment of its platform for digital health programs. Xealth spun out of Providence St. Joseph Health in 2017 and is led by CEO Mike McSherry; it is based in Seattle, Washington. It works with health systems including UPMC, the Froedtert and the Medical College of Wisconsin health network, Duke Health and other leading health systems. Xealth is a digital prescribing platform that enables clinicians to integrate, prescribe and monitor digital health tools for patients from their EHR workflows. Its platform supports patient education, online third-party apps and programs, device monitoring, and non-clinical services such as ride shares, food delivery and e-commerce recommendations. Care teams and physicians can monitor patient engagement and analyze the effects of more engaged patients. Originally incubated and spun out of Providence St. Joseph Health in 2017 and led by CEO Mike McSherry, the company is based in Seattle, WA. Xealth works with health systems including UPMC, the Froedtert and the Medical College of Wisconsin health network, Baylor Scott and White, and Duke. The company raised $11m in a Series A to accelerate expansion of its platform. Xealth is launching a digital prescribing and analytics platform that lets physicians and clinicians prescribe and track educational health content, disease-management apps, and monitoring devices directly from their EMR charting interface. The platform aggregates and filters a variety of content sources into a care provider’s existing EMR workflow, simplifying creation of a customized patient experience. Clinicians can discuss digital tools during appointments, track patient usage afterward, and schedule reminders to encourage engagement. Patients access prescribed digital health tools through their health system’s secure patient portal. Xealth was founded in 2016 by Mike McSherry and was incubated within Providence’s Digital Innovation Group. The company has raised $8.5M to support launch and expansion with participating health systems planning broader integration and use of third-party digital solutions.

Participated · Series B · Aug 2021

DiA Imaging Analysis, based in Beer Sheva, Israel, provides FDA-cleared and CE-marked AI-based ultrasound solutions that help clinicians capture the right images and automatically identify clinical abnormalities. Its vendor-neutral, cross-platform LVivo Toolbox is deployed on ultrasound devices and healthcare IT systems and currently serves thousands of end-users in more than 20 countries. The company announced an additional $14M in funding and plans to use the proceeds to expand its portfolio of solutions and grow its global presence in Asia, Europe and the U.S. It intends to pursue new and expanded partnerships with ultrasound vendors, PACS/Healthcare IT companies, resellers, and distributors. DiA has established channel and commercial partnerships with major healthcare technology providers and distributors including IBM Watson, Philips, GE Healthcare, and Konica Minolta. The company also added Dr. Diku Mandavia to its Board of Directors as an industry board member. DiA Imaging Analysis develops FDA- and CE-cleared cognitive image-processing software that provides fully automated ultrasound analysis, with its first product line focused on echocardiography. Its tools use advanced pattern recognition and machine-learning algorithms to automatically detect borders and motion and produce quantitative data for clinicians. The company integrates its software within ultrasound devices, healthcare IT systems and cloud platforms through partnerships with vendors including GE Healthcare, Neusoft Medical System and Google Cloud. DiA has reference sites at leading U.S. medical centers including Yale, Mount Sinai, RUSH, USF and UCSD, and its scientific advisory board is supported by cardiology and primary care ultrasound specialists. Founded by Hila Goldman Aslan (CEO), Michal Yaacobi (VP R&D) and Arnon Toussia-Cohen (VP BD), the Be'er Sheva–based company plans to expand its portfolio and build support teams in the United States, Europe and Asia. DiA closed a $5M funding round to support market penetration of its automated tools and further product development. DiACardio, founded in 2010 and based in Beer Sheva’s Hi-Tech Park, develops FDA- and CE-approved software that automatically evaluates heart function from ultrasound images. The company leverages new image-processing methods and proprietary algorithms to provide automated cardiac evaluation. DiACardio has 10 employees and has already obtained initial sales. It raised $1.95M in a post-seed financing to support growth. The company plans to use the funds to expand its automated toolbox to other areas of the heart and to grow its business in the US, Europe and emerging markets. The founding team includes Arnon Toussia-Cohen, Hila Goldman-Aslan, Michal Yaacobi, Dr. Noah Liel-Cohen and Prof. Hugo Guterman.